Abstract

Chronic obstructive pulmonary disease (COPD) is a progressive lung disease causing disability, which increases health care costs. In recent years enormous progress has been made to better understand treatment modalities for patients with COPD. This brief overview discusses the role and efficacy of combined long-acting β₂-agonists (LABAs) and long-acting muscarinic antagonists (LAMAs) in the management of COPD. Additionally, the overview analyses the indications and side-effects associated with the use of inhaled corticosteroids for patients with COPD.